Lilly acquires Ventyx Biosciences for $1.2 billion
Eli Lilly has agreed to acquire Ventyx Biosciences, a clinical-stage biopharmaceutical company focused on developing oral therapies for patients with inflammatory-mediated diseases. Ventyx is developing a pipeline of small molecule therapeutics, including NLRP3 inhibitors, designed to treat inflammation across a broad range of disease states with high… Read More